Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analysts: Five firms covering Bioventus have an average recommendation of Buy (1 hold, 3 buy, 1 strong buy) with a mean 12‑month price target of $14.25.
• Recent results: Bioventus beat expectations with EPS of $0.24 vs. $0.22 est. on revenue of $157.9M and set FY2026 guidance of $0.730–$0.770 EPS.
• Market snapshot: Shares traded at $8.60 (market cap $711.7M, P/E 26.06) and sit well below analysts' $14.25 target, with a 52‑week range of $5.81–$10.13.

Shares of Bioventus Inc. (NASDAQ:BVS - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $14.25.

Several research firms have commented on BVS. Craig Hallum boosted their price objective on Bioventus from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Friday, March 6th. Cantor Fitzgerald raised Bioventus to a "strong-buy" rating in a research note on Wednesday, March 4th. Barrington Research boosted their price target on Bioventus from $13.00 to $14.00 and gave the stock an "outperform" rating in a research report on Friday, March 6th. Finally, Weiss Ratings reissued a "hold (c-)" rating on shares of Bioventus in a research note on Monday, December 29th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Nantahala Capital Management LLC increased its stake in Bioventus by 28.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,280,842 shares of the company's stock worth $34,959,000 after buying an additional 1,155,192 shares during the period. Essex Investment Management Co. LLC acquired a new stake in shares of Bioventus in the fourth quarter valued at $2,886,000. Kent Lake PR LLC acquired a new stake in shares of Bioventus in the second quarter valued at $2,317,000. Kennedy Capital Management LLC boosted its holdings in Bioventus by 219.6% in the third quarter. Kennedy Capital Management LLC now owns 461,579 shares of the company's stock valued at $3,088,000 after purchasing an additional 317,157 shares during the period. Finally, Meros Investment Management LP acquired a new position in Bioventus during the 4th quarter worth $2,345,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Bioventus Stock Performance

Shares of BVS traded down $0.30 during trading hours on Thursday, hitting $8.60. The stock had a trading volume of 339,089 shares, compared to its average volume of 335,503. The firm has a market capitalization of $711.74 million, a price-to-earnings ratio of 26.06 and a beta of 0.78. The firm has a 50-day moving average price of $8.22 and a 200 day moving average price of $7.53. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.19 and a current ratio of 1.70. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $10.13.

Bioventus (NASDAQ:BVS - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.02. The firm had revenue of $157.90 million for the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.